Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

181. Cohort study: Statin potency associated with incident diabetes in a real-world evaluation

Cohort study: Statin potency associated with incident diabetes in a real-world evaluation Statin potency associated with incident diabetes in a real-world evaluation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Statin potency associated with incident diabetes in a real-world evaluation Article Text Aetiology Cohort study Statin potency associated with incident diabetes in a real-world evaluation Dylan L Steen , Deepak L Bhatt

2014 Evidence-Based Medicine (Requires free registration)

182. Systematic review and meta-analysis: Statins do not improve cardiovascular outcomes for dialysis patients

Systematic review and meta-analysis: Statins do not improve cardiovascular outcomes for dialysis patients Statins do not improve cardiovascular outcomes for dialysis patients | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Statins do not improve cardiovascular outcomes for dialysis patients Article Text Therapeutics Systematic review and meta-analysis Statins do not improve cardiovascular outcomes for dialysis patients Ali Olyaei

2014 Evidence-Based Medicine (Requires free registration)

183. Taking a statin to reduce the risk of coronary heart disease and stroke

Taking a statin to reduce the risk of coronary heart disease and stroke Statins to reduce the risk of CHD and stroke: patient decision aid Copyright © NICE 2014. All rights reserved. Last updated November 2014 Page 1 of 23 Taking a statin to reduce the risk of coronary heart disease and stroke http://www.nice.org.uk/guidance/cg181/resources/cg181-lipid-modification-update-patient-decision- aid2 Published: November 2014 About this decision aid This decision aid is intended to help you to make up (...) your mind whether or not to take a statin to help reduce your risk of having a heart attack or developing angina (together called coronary heart disease or CHD), or of having a stroke. Your decision depends on several things that this information will help to explain. Different people will feel that some of these things are more important to them than others, so it is important that you make a decision that is right for you. This decision aid is designed for you to work through with the healthcare

2014 Health Information and Quality Authority

184. Statins for cardiovascular disease

Statins for cardiovascular disease Probabilities of benefits and harms Patient preferences DECISION Later Yes No Questions to identify the patient's decision making needs: ? Do you have any questions about the benefits and harms of each option? ? Which benefits and harms matter most to you? ? Who will support and advise you in making a choice? ? Do you feel sure about the best choice for you? Presenting statins to patients What are statins for? Statins are medications taken daily to reduce (...) the concentrations of cholesterol in the blood and reduce the risks of having cardiovascular (CV) or cerebrosvascular (CeV) events. Among individuals who have never had cardiovascular disease (primary prevention), who might consider using statins? ? Adults at moderate to high risk of developing cardiovascular disease in the next 10 years. The probability of having a CV event in the next 10 years is evaluated using a risk calculator such as the Framingham Cardiac Risk Score* taking into account sex, age, diabetes

2014 Cancer Council Australia

185. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. (PubMed)

Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common causes of elevated liver enzymes in the general population. NASH and to some extent NAFLD have been associated with increased liver-related and all-cause mortality. No effective treatment is yet available. Recent reports have shown that the use of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins (...) ) in patients with elevated plasma aminotransferases may result in normalisation of these liver enzymes. Whether this is a consistent effect or whether it can lead to improved clinical outcomes beyond normalisation of abnormal liver enzymes is not clear.To assess the beneficial and harmful effects of statins (that is, lovastatin, atorvastatin, simvastatin, pravastatin, rosuvastatin, and fluvastatin) on all-cause and liver-related mortality, adverse events, and histological, biochemical, and imaging

2013 Cochrane

186. Statins and cognitive function: a systematic review

Statins and cognitive function: a systematic review Statins and cognitive function: a systematic review Statins and cognitive function: a systematic review Richardson K, Schoen M, French B, Umscheid CA, Mitchell MD, Arnold SE, Heidenreich PA, Rader DJ, deGoma EM CRD summary This review concluded that published data did not suggest an adverse effect of statins on cognition but the strength of available evidence was limited, particularly with regard to high-dose statins. The authors highlighted (...) some limitations in their review. The authors' cautious conclusions reflect the evidence presented and their recommendation for further research seems appropriate. Authors' objectives To examine the association between statin therapy and cognitive function. Searching PubMed, EMBASE and The Cochrane Library were searched from inception through October 2012 for studies published in English. Bibliographies of included studies were scanned. US Food and Drug Administration (FDA) databases were searched

2013 DARE.

187. Statins and cognitive function: a systematic review. (PubMed)

Statins and cognitive function: a systematic review. Despite the U.S. Food and Drug Administration (FDA) warning regarding cognitive impairment, the relationship between statins and cognition remains unknown.To examine the effect of statins on cognition.PubMed, Embase, and Cochrane Library from inception through October 2012; FDA databases from January 1986 through March 2012.Randomized, controlled trials (RCTs) and cohort, case-control, and cross-sectional studies evaluating cognition (...) in patients receiving statins.Two reviewers extracted data, 1 reviewer assessed study risk of bias, and 1 reviewer checked all assessments.Among statin users, low-quality evidence suggested no increased incidence of Alzheimer disease and no difference in cognitive performance related to procedural memory, attention, or motor speed. Moderate-quality evidence suggested no increased incidence of dementia or mild cognitive impairment or any change in cognitive performance related to global cognitive

2013 Annals of Internal Medicine

188. Are statins effective for primary prevention in people with low cardiovascular risk?

Are statins effective for primary prevention in people with low cardiovascular risk? Are statins effective for primary prevention in people with low cardiovascular risk? – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Share this: Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2014\/02\/statins-219x300.png"]} Toggle search form Toggle navigation Evidence-based medicine for general (...) practitioners Nov 08 2013 Are statins effective for primary prevention in people with low cardiovascular risk? By in , 8 November 2013 Journal reference: Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B, Klarenbach S, McAlister FA, Wiebe N, Manns B, Alberta Kidney Disease Network. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ 2011; 183(16): E1189-E1202 Link: Published: 24 October 2011 Evidence cookie says… Statins appear to have

2013 Morsels of Evidence

189. Effect of Statin Therapy on Mortality in Patients With Ventilator-Associated Pneumonia: A Randomized Clinical Trial. (PubMed)

Effect of Statin Therapy on Mortality in Patients With Ventilator-Associated Pneumonia: A Randomized Clinical Trial. Observational studies have reported that statin use may be associated with improved outcomes of various infections. Ventilator-associated pneumonia (VAP) is the most common infection in the intensive care unit (ICU) and is associated with substantial mortality.To determine whether statin therapy can decrease day-28 mortality in patients with VAP.Randomized, placebo-controlled (...) for futility at the first scheduled interim analysis after enrollment of 300 patients, of whom all but 7% in the simvastatin group and 11% in the placebo group were naive to statin therapy at ICU admission. Day-28 mortality was not lower in the simvastatin group (21.2% [95% CI, 15.4% to 28.6%) than in the placebo group (15.2% [95% CI, 10.2% to 22.1%]; P = .10; hazard ratio, 1.45 [95% CI, 0.83 to 2.51]); the between-group difference was 6.0% (95% CI, -3.0% to 14.9%). In statin-naive patients, day-28

Full Text available with Trip Pro

2013 JAMA

190. Meta-Analysis of Patients Taking Statins Before Revascularization and Aortic Valve Surgery (PubMed)

Meta-Analysis of Patients Taking Statins Before Revascularization and Aortic Valve Surgery Statin intake before cardiac surgery is associated with favorable outcomes. We sought to analyze the evidence for statin pretreatment before isolated coronary artery bypass graft surgery and aortic valve replacement surgery. In this meta-analysis, we demonstrate beneficial results for the endpoints mortality, stroke, atrial fibrillation, and length of stay in hospital in 36,053 statin-pretreated coronary (...) artery bypass graft surgery patients compared with control subjects retrieved from 32 studies, but fail to detect relevant advantages through preoperative statin therapy for 3,091 patients undergoing aortic valve replacement from four trials. Strict adherence to guidelines recommending statin treatment before CABG surgery is therefore mandatory. Copyright © 2013 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

2013 EvidenceUpdates

191. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular (...) Diagnostics. Bibliographic details McConnachie A, Walker A, Robertson M, Marchbank L, Peacock J, Packard CJ, Cobbe SM, Ford I. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. European Heart Journal 2014; 35(5): 290-298 PubMedID DOI Indexing Status Subject indexing assigned by NLM MeSH Cardiovascular Diseases /economics /prevention & Cost-Benefit Analysis; Health Resources

Full Text available with Trip Pro

2013 NHS Economic Evaluation Database.

192. HMG CoA reductase inhibitors (statins) for dialysis patients. (PubMed)

HMG CoA reductase inhibitors (statins) for dialysis patients. People with advanced kidney disease treated with dialysis experience mortality rates from cardiovascular disease that are substantially higher than for the general population. Studies that have assessed the benefits of statins (HMG CoA reductase inhibitors) report conflicting conclusions for people on dialysis and existing meta-analyses have not had sufficient power to determine whether the effects of statins vary with severity (...) of kidney disease. Recently, additional data for the effects of statins in dialysis patients have become available. This is an update of a review first published in 2004 and last updated in 2009.To assess the benefits and harms of statin use in adults who require dialysis (haemodialysis or peritoneal dialysis).We searched the Cochrane Renal Group's Specialised Register to 29 February 2012 through contact with the Trials' Search Co-ordinator using search terms relevant to this review.Randomised

Full Text available with Trip Pro

2013 Cochrane

193. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study (PubMed)

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study To assess the impact on healthcare resource utilization, costs, and quality of life over 15 years from 5 years of statin use in men without a history of myocardial infarction in the West of Scotland Coronary Prevention Study (WOSCOPS).Six thousand five hundred and ninety-five participants aged 45-54 years were randomized (...) failure and coronary revascularization. There was no excess in non-cardiovascular admissions or costs (or in admissions associated with diabetes or its complications) and no evidence of heterogeneity of effect over sub-groups defined by baseline cardiovascular risk.Five years' primary prevention treatment of middle-aged men with a statin significantly reduces healthcare resource utilization, is cost saving, and increases QALYs. Treatment of even younger, lower risk individuals is likely to be cost

Full Text available with Trip Pro

2013 EvidenceUpdates

194. Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery. (PubMed)

Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery. Patients undergoing vascular surgery are a high-risk population with widespread atherosclerosis, an adverse cardiovascular risk profile and often multiple co-morbidities. Postoperative cardiovascular complications, including myocardial infarct (MI), are common. Statins are the medical treatment of choice to reduce high cholesterol levels. Evidence is accumulating that patients taking statins (...) at the time of surgery are protected against a range of perioperative complications, but the specific benefits for patients undergoing noncardiac vascular surgery are not clear.We examined whether short-term statin therapy, commenced before or on the day of noncardiac vascular surgery and continuing for at least 48 hours afterwards, improves patient outcomes including the risk of complications, pain, quality of life and length of hospital stay. We also examined whether the effect of statin therapy

Full Text available with Trip Pro

2013 Cochrane

195. Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials

Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials Fauchier L, Clementy N, Babuty D CRD summary This review concluded that statins reduced the risk of atrial fibrillation (...) in patients with sinus rhythm; the greatest benefit was in prevention of postoperative atrial fibrillation and secondary prevention of atrial fibrillation. Given the variability across studies, limitations of the evidence available, and lack of reporting of the review process, reliability of the review's conclusions is uncertain. Authors' objectives To investigate whether statins can prevent atrial fibrillation. Searching MEDLINE and EMBASE were searched for studies published in English in peer-reviewed

Full Text available with Trip Pro

2013 DARE.

196. High-Dose Statin Therapy in Patients With Stable Coronary Artery Disease: Treating the Right Patients Based on Individualized Prediction of Treatment Effect (PubMed)

High-Dose Statin Therapy in Patients With Stable Coronary Artery Disease: Treating the Right Patients Based on Individualized Prediction of Treatment Effect Clinicians need to identify coronary artery disease patients for whom the benefits of high-dose versus usual-dose statin therapy outweigh potential harm. We therefore aimed to develop and validate a model for prediction of the incremental treatment effect of high-dose statins for individual patients in terms of reduction of 5-year absolute (...) needed to treat was ≥50. A decision curve shows that making treatment decisions on the basis of predictions using our model may improve net benefit.Estimation of the incremental treatment effect of high-dose versus usual-dose statin therapy in individual coronary artery disease patients enables selection of high-risk patients that benefit most from more aggressive therapy.http://www.clinicaltrials.gov. Unique identifiers: NCT00327691 and NCT00159835.

Full Text available with Trip Pro

2013 EvidenceUpdates

197. Statins and the risk of interstitial lung disease: a cohort study (PubMed)

Statins and the risk of interstitial lung disease: a cohort study Case reports have suggested that the use of statins may be associated with an increase in the risk of interstitial lung disease (ILD).Within a large cohort of users of respiratory medications identified in the Quebec health administrative databases during 1990-2005, we carried out a nested case-control analysis of the relationship between statins and the risk of ILD as defined by specialist visits or hospitalisations.The cohort (...) included over 1.4 million patients, of which 6665 possible or probable cases of ILD were identified during follow-up. These were compared with 26 660 controls matched for age, gender and calendar time. After adjustment for confounders and comorbid conditions, there was no association between current use of statins and risk of ILD (adjusted OR 0.99, 95% CI 0.91 to 1.08). The results were similar when any use of statins within the previous 1 or 2 years was considered or when the analysis was limited

Full Text available with Trip Pro

2013 EvidenceUpdates

198. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. (PubMed)

Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Clarithromycin and erythromycin, but not azithromycin, inhibit cytochrome P450 isoenzyme 3A4 (CYP3A4), and inhibition increases blood concentrations of statins that are metabolized by CYP3A4.To measure the frequency of statin toxicity after coprescription of a statin with clarithromycin or erythromycin.Population-based cohort study.Ontario, Canada, from 2003 to 2010.Continuous statin users older than 65 (...) years who were prescribed clarithromycin (n = 72,591) or erythromycin (n = 3267) compared with those prescribed azithromycin (n = 68,478).The primary outcome was hospitalization with rhabdomyolysis within 30 days of the antibiotic prescription.Atorvastatin was the most commonly prescribed statin (73%) followed by simvastatin and lovastatin. Compared with azithromycin, coprescription of a statin with clarithromycin or erythromycin was associated with a higher risk for hospitalization

2013 Annals of Internal Medicine

199. Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis (PubMed)

Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Several studies have shown that statins could have chemopreventive effects on HCC. We performed a systematic review and meta-analysis of studies that evaluated the effects of statins on the risk of HCC.We conducted a systematic search of MEDLINE, Embase, and Web of Science through May 2012 and manually (...) reviewed the literature. Studies were included if they evaluated and clearly defined exposure to statins, reported the incidence of HCC, and reported relative risks or odds ratios (ORs) or provided data for their estimation. Ten studies reporting 4298 cases of HCC in 1,459,417 patients were analyzed. Summary OR estimates with 95% confidence intervals (CIs) were calculated using the random effects model. Statistical heterogeneity was assessed with the Cochran's Q statistic and I(2) statistic.Statin

2013 EvidenceUpdates

200. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis (PubMed)

Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis The effects of statin therapy in patients with chronic kidney disease (CKD) remain uncertain. We undertook a systematic review and meta-analysis to investigate the effects of statin on major clinical outcomes.We systematically searched MEDLINE, Embase, and the Cochrane Library for trials published between 1970 and November 2011. We included prospective (...) , randomized, controlled trials assessing the effects of statins on cardiovascular outcomes in people with kidney disease. Summary estimates of relative risk (RR) reductions were calculated with a random effects model. Thirty-one trials that include at least one event were identified, providing data for 48 429 patients with CKD, including 6690 major cardiovascular events and 6653 deaths. Statin therapy produced a 23% RR reduction (16-30) for major cardiovascular events (P<0.001), an 18% RR reduction (8-27

Full Text available with Trip Pro

2013 EvidenceUpdates